CN116515682A - Strain, method for extracting fenugreek, preparation method and application of fenugreek extract - Google Patents
Strain, method for extracting fenugreek, preparation method and application of fenugreek extract Download PDFInfo
- Publication number
- CN116515682A CN116515682A CN202310288547.5A CN202310288547A CN116515682A CN 116515682 A CN116515682 A CN 116515682A CN 202310288547 A CN202310288547 A CN 202310288547A CN 116515682 A CN116515682 A CN 116515682A
- Authority
- CN
- China
- Prior art keywords
- fenugreek
- supernatant
- extract
- strain
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000250129 Trigonella foenum graecum Species 0.000 title claims abstract description 87
- 235000001484 Trigonella foenum graecum Nutrition 0.000 title claims abstract description 87
- 235000001019 trigonella foenum-graecum Nutrition 0.000 title claims abstract description 87
- 235000020765 fenugreek extract Nutrition 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims description 21
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 150000004676 glycans Chemical class 0.000 claims abstract description 29
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 29
- 239000005017 polysaccharide Substances 0.000 claims abstract description 29
- 239000000843 powder Substances 0.000 claims abstract description 24
- 108090000790 Enzymes Proteins 0.000 claims abstract description 21
- 102000004190 Enzymes Human genes 0.000 claims abstract description 21
- 239000000284 extract Substances 0.000 claims abstract description 20
- 238000000605 extraction Methods 0.000 claims abstract description 19
- 241000592795 Paenibacillus sp. Species 0.000 claims abstract description 18
- 229940098465 tincture Drugs 0.000 claims abstract description 17
- 230000000593 degrading effect Effects 0.000 claims abstract description 14
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 9
- 238000004321 preservation Methods 0.000 claims abstract description 9
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 5
- 239000006228 supernatant Substances 0.000 claims description 46
- 239000001963 growth medium Substances 0.000 claims description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 17
- 230000001954 sterilising effect Effects 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 9
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 9
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 9
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 9
- 239000001110 calcium chloride Substances 0.000 claims description 9
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 9
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 9
- 210000000582 semen Anatomy 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 9
- 229960001763 zinc sulfate Drugs 0.000 claims description 9
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 9
- 239000001888 Peptone Substances 0.000 claims description 8
- 108010080698 Peptones Proteins 0.000 claims description 8
- 238000000855 fermentation Methods 0.000 claims description 8
- 230000004151 fermentation Effects 0.000 claims description 8
- 235000019319 peptone Nutrition 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 230000003213 activating effect Effects 0.000 claims description 5
- 230000006698 induction Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 3
- 241001312519 Trigonella Species 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 238000012387 aerosolization Methods 0.000 claims description 3
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 235000014101 wine Nutrition 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 241000208125 Nicotiana Species 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 11
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 10
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 6
- 230000002292 Radical scavenging effect Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 4
- HDXIQHTUNGFJIC-UHFFFAOYSA-N (25R)-spirost-5-en-3beta-ol 3-O-<O-alpha-L-rhamnopyranosyl-(1-->2)-beta-D-glucopyranoside> Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O HDXIQHTUNGFJIC-UHFFFAOYSA-N 0.000 description 3
- LWFUFLREGJMOIZ-UHFFFAOYSA-N 3,5-dinitrosalicylic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O LWFUFLREGJMOIZ-UHFFFAOYSA-N 0.000 description 3
- VNONINPVFQTJOC-RXEYMUOJSA-N Collettiside III Natural products O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 VNONINPVFQTJOC-RXEYMUOJSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- VNONINPVFQTJOC-ZGXDEBHDSA-N dioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O VNONINPVFQTJOC-ZGXDEBHDSA-N 0.000 description 3
- CJNUQCDDINHHHD-APRUHSSNSA-N dioscin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@H]6[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O CJNUQCDDINHHHD-APRUHSSNSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- VNONINPVFQTJOC-UHFFFAOYSA-N polyphyllin III Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O VNONINPVFQTJOC-UHFFFAOYSA-N 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OSCCDBFHNMXNME-WDCZJNDASA-N (2s,3s,4r)-2-amino-4-hydroxy-3-methylpentanoic acid Chemical compound C[C@@H](O)[C@@H](C)[C@H](N)C(O)=O OSCCDBFHNMXNME-WDCZJNDASA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- OSCCDBFHNMXNME-UHFFFAOYSA-N gamma-hydroxyisoleucine Natural products CC(O)C(C)C(N)C(O)=O OSCCDBFHNMXNME-UHFFFAOYSA-N 0.000 description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000005787 Cistanche Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000179039 Paenibacillus Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/022—Powders; Compacted Powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G3/00—Preparation of other alcoholic beverages
- C12G3/04—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs
- C12G3/05—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs with health-improving ingredients, e.g. flavonoids, flavones, polyphenols or polysaccharides
- C12G3/055—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs with health-improving ingredients, e.g. flavonoids, flavones, polyphenols or polysaccharides extracted from plants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Botany (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention provides a strain, which is Paenibacillus sp.XD-85, the preservation unit is CCTCC, and the preservation number is CCTCC NO: M20221060. The invention also provides an extraction method of the fenugreek, a preparation method of the fenugreek extract, a preparation method of the fenugreek tincture, a preparation method of the fenugreek extract powder and application. The invention adopts the compound solution of the fenugreek gum to culture the strain to induce the production of the fenugreek polysaccharide degrading enzyme, and uses the induced degrading enzyme to carry out biological extraction of the fenugreek to obtain the extract, thus having short extraction time, high extraction rate and anti-inflammatory and antioxidant activities.
Description
Technical Field
The invention relates to the technical field of biology, in particular to a strain, a method for extracting fenugreek, a method for preparing a fenugreek extract and application, and more particularly relates to a method for preparing a fenugreek extract, a method for preparing fenugreek tincture and a method for preparing fenugreek extract powder.
Background
Fenugreek (Trigonella foenum-graeeum, l.), also known as herba cistanches, alfalfa, is a family of the fagopterus dung of the leguminous plant, and is widely used as a spice and flavoring agent in people's daily life. Fenugreek is bitter in taste and warm in nature, and has the effects of warming kidney, dispelling cold and relieving pain. Because of the complex chemical components and wide pharmacological actions, the Chinese pharmacopoeia records multiple versions, and the dioscin in the fenugreek consists of hydrophilic sugar bodies and hydrophobic sapogenins; in the aspect of traditional Chinese medicine application, the diosgenin is a typical natural sapogenin compound and has the effects of relaxing tendons, activating blood circulation, promoting digestion, promoting diuresis, desensitizing, resisting inflammation, resisting tumor, resisting viruses and the like; the traditional Chinese medicine holds that the diosgenin has the effects of inhibiting inflammation and oxidation resistance, and is applied to the effects of eliminating phlegm, relaxing tendons, promoting blood circulation, protecting liver and the like; since the fenugreek seeds contain a large amount of polysaccharide, protein and other substances, the diosgenin and cellulose are combined and exist in tough cell walls, and the dissolution of the diosgenin is greatly hindered, so that when the fenugreek seeds are treated by adopting a traditional extraction method, the extraction rate of the diosgenin is not high, and the defects of long extraction time, complex process flow and the like exist.
Disclosure of Invention
Aiming at one or more of the problems in the prior art, the invention provides a strain, wherein the strain is Paenibacillus sp.XD-85, the preservation unit is CCTCC, and the preservation number is CCTCC NO: M20221060.
According to one aspect of the invention, the fermentation broth of the strain is capable of converting the trigonella polysaccharide to yield the product 1:1 galactomannotetraose.
According to a second aspect of the present invention, there is provided a method of extracting fenugreek, comprising:
activating the Paenibacillus sp.XD-85 strain;
the activated strain is added to fenugreek such that fenugreek polysaccharide is degraded by polysaccharide degrading enzymes to produce 1:1 galactomanntetraose.
According to a second aspect of the present invention, the step of activating the Paenibacillus sp.xd-85 strain comprises:
the pure culture of the Paenibacillus sp.XD-85 strain degraded on the fenugreek gum induction culture medium is inoculated into the culture medium, and the culture medium is subjected to shaking culture for 20 to 30 hours at the temperature of 31 to 33 ℃ and at the speed of 150 to 170 r/min; preferably, the pure culture of the Paenibacillus sp.XD-85 strain degraded on the fenugreek gum induction culture medium is inoculated into the culture medium, and the culture medium is subjected to shaking culture for 24 hours at the temperature of 32 ℃ at 160 r/min;
preferably, the culture medium comprises zinc sulfate, ammonium sulfate, sodium chloride, calcium chloride, dipotassium hydrogen phosphate, fenugreek gum, sucrose, peptone and water, and further preferably, the mass ratio of the zinc sulfate, the ammonium sulfate, the sodium chloride, the calcium chloride, the dipotassium hydrogen phosphate, the fenugreek gum, the sucrose and the peptone is (15-17): (290-310): (290-310): (4-6): (90-110): (40-60): (400-600): (200-400); still more preferably, the medium consists of 1000ml of water containing 5g of sucrose, 0.16g of zinc sulfate, 3g of ammonium sulfate, 3g of sodium chloride, 0.05g of calcium chloride, 1g of dipotassium hydrogen phosphate, 0.5g of fenugreek gum and 3g of peptone.
According to a second aspect of the present invention, the step of adding the activated strain to the fenugreek further comprises treating the fenugreek to a paste.
Preferably, the step of processing the fenugreek into a paste comprises:
pulverizing semen Trigonellae, and sieving to obtain semen Trigonellae powder smaller than 80 mesh;
according to the concentration of 2% -4%, the fenugreek powder is dissolved into uniform paste at 70-90 ℃ and cooled to 40-60 ℃; preferably, the fenugreek powder is dissolved in hot water at 80 ℃ to a uniform paste at a concentration of 3%, and cooled to 50 ℃.
According to a second aspect of the invention, the step of adding the activated strain to fenugreek such that fenugreek polysaccharide is degraded by a polysaccharide degrading enzyme to produce 1:1 galactomanntetraose comprises:
adding activated strain according to 4-6% of the volume of the fenugreek, stirring and preserving heat for 30-50 ℃ and extracting for 2-4 hours, wherein the fenugreek polysaccharide is degraded by polysaccharide degrading enzyme in the extraction process to generate 1:1 galactomanntetraose, stopping the reaction when the viscosity is less than 10Pa.s, sterilizing, and carrying out centrifugal separation to obtain solid-liquid retention supernatant, wherein the supernatant is the fenugreek extract containing 1:1 galactomanntetraose; preferably, adding activated strain according to 5% of the volume of the fenugreek, stirring and preserving heat at 40 ℃ for 3 hours, wherein the extraction process enables the fenugreek polysaccharide to be degraded by polysaccharide degrading enzyme to generate 1:1 galactomanntetraose, stopping the reaction when the viscosity is less than 10Pa.s, sterilizing, and preserving supernatant by centrifugal separation, wherein the supernatant is the fenugreek extract containing 1:1 galactomanntetraose; preferably, the sterilizing pressure is 1-1.1 kg/cm, the temperature is 120-125 ℃, and the sterilizing time is 10-20 minutes; further preferably, the sterilization pressure is 1.05kg/cm, the temperature is 121℃and the sterilization time is 15 minutes.
According to a third aspect of the present invention, there is provided a method for preparing a fenugreek extract, comprising:
concentrating the supernatant under reduced pressure to obtain a supernatant containing extract solids, preferably with an extract solids content of greater than 36%;
performing antiseptic treatment on the supernatant containing the extract solids to obtain the fenugreek extract.
According to a third aspect of the present invention, the step of concentrating the supernatant under reduced pressure comprises:
concentrating the supernatant 5-15 times, wherein the temperature of reduced pressure concentration is 50-70 ℃, and the concentration pressure is-0.08 to-0.06 MPa; preferably, the supernatant is concentrated 10 times at a reduced pressure of 60℃and a concentration pressure of-0.07 MPa.
According to a fourth aspect of the present invention, there is provided a method for preparing a fenugreek tincture, comprising:
concentrating the supernatant under reduced pressure to obtain a supernatant containing extract solids, preferably with an extract solids content of greater than 36%;
adding ethanol into the supernatant containing extract solids, dissolving, separating to remove precipitate to obtain semen Trigonellae tincture, preferably adding ethanol at 30-70% of the volume of the supernatant, dissolving thoroughly, and separating the supernatant again to obtain semen Trigonellae tincture.
According to a fourth aspect of the present invention, the step of concentrating the supernatant under reduced pressure comprises:
concentrating the supernatant by 3-7 times, wherein the temperature of reduced pressure concentration is 50-70 ℃, and the concentration pressure is minus 0.08-minus 0.06MPa; preferably, the supernatant is concentrated 5-fold at a reduced pressure of 60℃and a concentration pressure of-0.07 MPa.
According to a fifth aspect of the present invention, there is provided a method for preparing a powder of fenugreek extract, comprising:
spray drying the supernatant to obtain fenugreek extract powder, wherein the spray drying is to disperse feed liquid by using a sprayer, when the feed liquid is dispersed into fine fogdrops, the fine fogdrops are contacted with hot air and then are dried rapidly, and finally, the finished product fenugreek extract powder is obtained through separation, recovery and cooling, and preferably, the air inlet temperature of the spray drying is 150-180 ℃ and the air outlet temperature is 90-106 ℃; further preferably, the air inlet temperature of the spray drying is 165 ℃ and the air outlet temperature is 98 ℃;
preferably, the water content of the fenugreek extract powder is <6%.
According to a sixth aspect of the present invention, there is provided the use of the above mentioned trigonella foenum-graecum extract, the above mentioned trigonella foenum-graecum tincture or/and the above mentioned trigonella foenum-graecum extract powder in tobacco, electronic aerosolization additives, wines, drinks or cosmetics, said trigonella foenum-graecum extract, trigonella foenum-graecum tincture or/and said trigonella foenum-graecum extract powder having anti-inflammatory and anti-oxidative effects.
The invention utilizes the characteristic microorganism (Paenibacillus sp. XD-85 strain) of the liquefied fenugreek gum, the microorganism has the characteristic of producing 1:1 galactomannite tetraose by specific induced fermentation to degrade the fenugreek gum, the viscosity of the fenugreek is greatly reduced by the comprehensive degradation of the fermentation product, the diosgenin is fully released, the active substance components and the activity of the product are increased, and the invention has the advantages of short extraction time, high extraction rate, production of new active components, easy release of the active components, environmental protection and the like.
According to the invention, the fenugreek is extracted through enzymatic conversion, and the fenugreek polysaccharide is degraded to generate 1:1 galactomanntetraose in the extraction process, so that the polysaccharide viscosity is lost, and meanwhile, the dioscin is dissociated to release the diosgenin; the extract can be further prepared into fenugreek tincture, fenugreek extract and fenugreek powder through supernatant liquid of solid-liquid separation, the purpose of the invention is to comprehensively degrade the fenugreek through the fermentation product, greatly reduce the viscosity of the fenugreek extract, fully release active substance components of products such as diosgenin, 4-hydroxyisoleucine and the like and play an active role, and the invention has the advantages of short extraction time, high extraction rate, novel active component generation, easy release and recovery of the active component, green environmental protection and the like, and the paste, tincture and powder extracted by the technology have good prospects in application to tobacco, electronic aerosolization additives, wines, drinks and cosmetics.
Detailed Description
Hereinafter, only certain exemplary embodiments are briefly described. As will be recognized by those of skill in the pertinent art, the described embodiments may be modified in various different ways without departing from the spirit or scope of the present invention.
The following description of the preferred embodiments of the present invention is provided for the purpose of illustration and explanation only and is not intended to limit the present invention.
Example 1
1) Obtaining a strain with fenugreek polysaccharide, in particular: collecting soil of fenugreek in a planting field, carrying out grinding and crushing on 100g of the soil, vanilla, fenugreek and fenugreek products, adding 1% of the ground and crushing into mother liquor (the mother liquor is composed of 100ml of water containing 0.16g of zinc sulfate, 3g of ammonium sulfate, 3g of sodium chloride, 0.05g of calcium chloride, 1g of dipotassium hydrogen phosphate and 0.5g of fenugreek gum), placing the mother liquor in a 37 ℃ incubator for enrichment culture for 24 hours, taking a solid culture medium composed of 100ml of water containing 0.16g of zinc sulfate, 3g of ammonium sulfate, 3g of sodium chloride, 0.05g of calcium chloride, 1g of dipotassium hydrogen phosphate, 0.5g of fenugreek gum, 0.3 g of yeast extract, 3g of peptone and 1.2 agar, taking an enrichment culture solution by an inoculating loop, carrying out plate streaking separation on a solid culture medium plate, culturing for 48 hours at 32 ℃, observing colony morphology, taking a colony streaking plate with an obvious transparent ring, and culturing for 48 hours to obtain XD 85 strain. PCR amplification was performed using genomic DNA of strain XD-85 as a template and a bacterial 16SrRNA gene sequence universal primer to obtain a 16S rDNA gene sequence of 1448bp in length, blast was performed in EzTaxon database (www.ezbiocloud.net), and the result showed that the strain was Paenibacillus sp, designated Paenibacillus sp. The strain is delivered to China Center for Type Culture Collection (CCTCC) for preservation, wherein the preservation time is 2022, 07 and 08, and the preservation number is CCTCC NO: M20221060.
The fermentation capacity of the Paenibacillus sp.XD-85 strain of step 1) was measured, specifically:
adding 0.1ml of fermentation liquor into a colorimetric tube containing 1ml of fenugreek gum substrate at 0.5g/L, and carrying out water bath reaction at 37 ℃ for 30min to obtain reaction liquor;
the control group was mixed with 0.1ml of inactivated enzyme solution and 1ml of substrate solution;
the increasing amount of reducing sugar in the reaction liquid is used as an index for detecting the enzyme activity, and the DNS (3, 5-dinitrosalicylic acid) method is adopted for measuring the reducing sugar: 1ml of the reaction solution was taken, 1ml of DNS solution was added, after a boiling water bath reaction was carried out for 5 minutes, the reaction solution was cooled, the reaction solution was fixed to 25ml, distilled water was used as a blank, and the absorbance was measured at 520 nm. Glucose is used as a standard curve, and the production amount of reducing sugar is calculated according to the difference value of the absorbance values of the reaction group and the control group; 1 enzyme activity unit (U) is defined as the amount of enzyme required to produce 1. Mu.g of reducing sugar (in galactose) per minute at 32 ℃):
enzyme activity=m×n×1000/(t×l)
M: amount of reducing sugar (mg)
N: multiple of enzyme dilution
T: time of reaction (min)
L: milliliters (mL) of enzyme solution tested;
the polysaccharide has a structural general formula:
the initial enzyme activity unit of the Paenibacillus sp.XD-85 strain is 100U/ml;
2) Activation of the Paenibacillus sp.XD-85 Strain, specifically:
inoculating pure culture of the Paenibacillus sp.XD-85 strain obtained in the step 1) on a fenugreek gum induction culture medium to the culture medium (30 ml of liquid in a 100ml triangular flask), and carrying out shake culture at the temperature of 32 ℃ for 24 hours at 160r/min to obtain a culture, wherein the culture medium is prepared from 5g of sucrose, 0.16g of zinc sulfate, 3g of ammonium sulfate, 3g of sodium chloride, 0.05g of calcium chloride, 1g of dipotassium hydrogen phosphate, 0.5g of fenugreek gum and 3g of peptone in 1000ml of water;
3) Advanced treatment of fenugreek, specifically: pulverizing semen Trigonellae to obtain powder with a particle size of less than 80 meshes, dissolving in hot water at 80deg.C to obtain uniform paste, and cooling to 50deg.C;
4) Adding 5% of the volume of the paste-like fenugreek into the culture in the step 1), stirring, preserving heat at 40 ℃ for 3 hours, degrading the fenugreek polysaccharide by polysaccharide degrading enzyme to generate 1:1 galactomanntetraose, stopping the reaction when the viscosity is less than 10Pa.s, sterilizing at the sterilizing pressure of 1.05kg/cm and the sterilizing temperature of 121 ℃ for 15 minutes, separating solid and liquid by centrifugation after sterilization, and retaining supernatant, wherein the supernatant is the fenugreek extract containing 1:1 galactomanntetraose;
the structural formula of the 1:1 galactomanntetraose is as follows:
the analysis of the galactomannans is to degrade the trigonelline sugar, and the obtained degradation products are determined by separation and purification mass spectrometry analysis;
5) Preparing a fenugreek extract, concentrating the supernatant obtained in the step 4) at 60 ℃ and-0.07 MPa for 10 times to form an extract with the solid content of 36 percent, and carrying out antiseptic treatment to obtain the fenugreek extract;
6) Preparing fenugreek tincture, concentrating the supernatant in the step 4) at 60 ℃ and-0.07 MPa for 5 times, adding food-grade ethanol according to the ethanol content of 30% -70% by taking the solid content of the extract as a content standard, fully dissolving, and separating the supernatant to obtain the fenugreek tincture;
7) Preparing fenugreek extract powder, and spray drying the supernatant obtained in the step 4) under the conditions that the air inlet temperature is 165 ℃ and the air outlet temperature is 98 ℃ until the water content is < 5%.
The anti-inflammatory activity of the fenugreek extract containing 1:1 galactomanntetraose of step 4) was assessed by means of LPS-induced macrophage inflammatory model (traditional Chinese medicine pharmacology, people health Press) compared to non-enzymatically transformed extract, in particular:
the fenugreek extract containing 1:1 galactotetraose of step 4) was formulated at a concentration of 0.1% as a test substance;
the non-enzymatic conversion extract was formulated at a concentration of 0.1% as a control;
in-vitro anti-inflammatory activity evaluation is carried out, nitric Oxide (NO) in an LPS-induced macrophage inflammation model system has the dual characteristics of promoting inflammation and resisting inflammation, a large amount of NO which is obviously generated possibly builds a defense line for defending invasion of cells, viruses, parasites and the like in inflammatory reaction, meanwhile, nonspecific immunity of NO can invade tissue pathogens, and can kill tumor cells, induce apoptosis of the tumor cells, when the cells are stimulated by inflammation, a test object has obvious effect of inhibiting TNF-a generation compared with a control group, TNF-alpha is a cytokine with various biological activities and is mainly secreted by activated macrophages, besides the anti-tumor and antiviral effects, the anti-inflammatory cytokine also indicates that the test object has obvious anti-inflammatory effect, the control group does not inhibit TNF-a generation, and the anti-inflammatory effect of the control group is not obvious.
In this example, according to the in vitro measurement index based on antioxidant activity in the "health food function evaluation method (2020 edition)", the in vitro antioxidant activity evaluation is performed on the fenugreek extract containing 1:1 galactomannotetraose in step 4), and the result of the hydroxyl radical scavenging effect evaluation is: hydroxyl radical scavenging at a concentration of 3mg/ml was 87.99%; DPPH radical scavenging Effect evaluation DPPH radical scavenging 60.91%; ABTS radical scavenging effect evaluation: 5mg/ml extract was 77.24% free radical ABTS scavenging.
According to the invention, the fenugreek gum compound solution is adopted to culture the strain to induce the generation of fenugreek polysaccharide degrading enzyme, the fenugreek polysaccharide is degraded by utilizing the induced degrading enzyme to generate 1:1 galactomanntetraose in the extraction process, the polysaccharide viscosity is lost, and the dissociated dioscin releases diosgenin; the extract can be further prepared into fenugreek tincture, fenugreek extract and fenugreek powder through supernatant liquid of solid-liquid separation, and the method has the advantages of short extraction time, high extraction rate, novel active ingredient generation, easiness in active ingredient release, recovery, green and environment-friendly performance and the like through comprehensive degradation of the fenugreek by the aid of the Paenibacillus sp.XD-85 fermentation product, the viscosity and average molecular weight of the fenugreek extract are greatly reduced, active substance components of products such as diosgenin, 4-hydroxyisoleucine and the like are fully released, the active effect is exerted, and the main product galactomannitose is obtained through activity detection such as anti-inflammatory and anti-oxidation.
The foregoing is a preferred embodiment of the present invention, and although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that modifications may be made to the technical solutions described in the foregoing embodiments, or equivalents may be substituted for some of the technical features thereof. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. A strain is characterized in that the strain is Paenibacillus sp.XD-85, the preservation unit is CCTCC, and the preservation number is CCTCC NO: M20221060.
2. The strain of claim 1, wherein the fermentation broth of the strain is capable of converting trigonella polysaccharides to yield a 1:1 galactomannotetraose product.
3. A method of extracting fenugreek, comprising:
activating the Paenibacillus sp.xd-85 strain of claim 1;
adding the activated strain into fenugreek, so that fenugreek polysaccharide is degraded by polysaccharide degrading enzyme to generate 1:1 galactomanntetraose;
preferably, the step of activating the Paenibacillus sp.xd-85 strain of claim 1 comprises:
the pure culture of the Paenibacillus sp.XD-85 strain degraded on the fenugreek gum induction culture medium is inoculated into the culture medium, and the culture medium is subjected to shaking culture for 20 to 30 hours at the temperature of 31 to 33 ℃ and at the speed of 150 to 170 r/min; preferably, the pure culture of the Paenibacillus sp.XD-85 strain degraded on the fenugreek gum induction culture medium is inoculated into the culture medium, and the culture medium is subjected to shaking culture for 24 hours at the temperature of 32 ℃ at 160 r/min;
preferably, the culture medium comprises zinc sulfate, ammonium sulfate, sodium chloride, calcium chloride, dipotassium hydrogen phosphate, fenugreek gum, sucrose, peptone and water, and further preferably, the mass ratio of the zinc sulfate, the ammonium sulfate, the sodium chloride, the calcium chloride, the dipotassium hydrogen phosphate, the fenugreek gum, the sucrose and the peptone is (15-17): (290-310): (290-310): (4-6): (90-110): (40-60): (400-600): (200-400); still more preferably, the culture medium consists of 1000ml of water containing 5g of sucrose, 0.16g of zinc sulfate, 3g of ammonium sulfate, 3g of sodium chloride, 0.05g of calcium chloride, 1g of dipotassium hydrogen phosphate, 0.5g of fenugreek gum and 3g of peptone;
preferably, the step of adding the activated strain to the fenugreek further comprises treating the fenugreek to form a paste;
further preferably, the step of processing the fenugreek into a paste comprises:
pulverizing semen Trigonellae, and sieving to obtain semen Trigonellae powder smaller than 80 mesh;
according to the concentration of 2% -4%, the fenugreek powder is dissolved into uniform paste at 70-90 ℃ and cooled to 40-60 ℃; preferably, the fenugreek powder is dissolved in hot water at 80 ℃ to a uniform paste at a concentration of 3%, and cooled to 50 ℃.
4. A method of extracting fenugreek according to claim 3, wherein the step of adding the activated strain to fenugreek such that the fenugreek polysaccharide is degraded by polysaccharide degrading enzymes to produce 1:1 galactomanntetraose comprises:
adding activated strain according to 4-6% of the volume of the fenugreek, stirring and preserving heat for 30-50 ℃ and extracting for 2-4 hours, wherein the fenugreek polysaccharide is degraded by polysaccharide degrading enzyme in the extraction process to generate 1:1 galactomanntetraose, stopping the reaction when the viscosity is less than 10Pa.s, sterilizing, and carrying out centrifugal separation to obtain solid-liquid retention supernatant, wherein the supernatant is the fenugreek extract containing 1:1 galactomanntetraose; preferably, adding activated strain according to 5% of the volume of the fenugreek, stirring and preserving heat at 40 ℃ for 3 hours, wherein the extraction process enables the fenugreek polysaccharide to be degraded by polysaccharide degrading enzyme to generate 1:1 galactomanntetraose, stopping the reaction when the viscosity is less than 10Pa.s, sterilizing, and preserving supernatant by centrifugal separation, wherein the supernatant is the fenugreek extract containing 1:1 galactomanntetraose; preferably, the sterilizing pressure is 1-1.1 kg/cm, the temperature is 120-125 ℃, and the sterilizing time is 10-20 minutes; further preferably, the sterilization pressure is 1.05kg/cm, the temperature is 121℃and the sterilization time is 15 minutes.
5. A method for preparing fenugreek extract, which is characterized by comprising the following steps:
concentrating the supernatant of claim 4 under reduced pressure to obtain a supernatant comprising extract solids, preferably having an extract solids content of greater than 36%;
performing antiseptic treatment on the supernatant containing the extract solids to obtain the fenugreek extract.
6. The method according to claim 5, wherein the step of concentrating the supernatant according to claim 4 under reduced pressure comprises:
concentrating the supernatant 5-15 times, wherein the temperature of reduced pressure concentration is 50-70 ℃, and the concentration pressure is-0.08 to-0.06 MPa; preferably, the supernatant is concentrated 10 times at a reduced pressure of 60℃and a concentration pressure of-0.07 MPa.
7. A method for preparing fenugreek tincture, which is characterized by comprising the following steps:
concentrating the supernatant of claim 4 under reduced pressure to obtain a supernatant comprising extract solids, preferably having an extract solids content of greater than 36%;
adding ethanol into the supernatant containing extract solids, dissolving, separating to remove precipitate to obtain semen Trigonellae tincture, preferably adding ethanol at 30-70% of the volume of the supernatant, dissolving thoroughly, and separating the supernatant again to obtain semen Trigonellae tincture.
8. The method according to claim 7, wherein the step of concentrating the supernatant according to claim 4 under reduced pressure comprises:
concentrating the supernatant by 3-7 times, wherein the temperature of reduced pressure concentration is 50-70 ℃, and the concentration pressure is minus 0.08-minus 0.06MPa; preferably, the supernatant is concentrated 5-fold at a reduced pressure of 60℃and a concentration pressure of-0.07 MPa.
9. A method for preparing fenugreek extract powder, which is characterized by comprising the following steps:
spray-drying the supernatant according to claim 4 to obtain a powder of the fenugreek extract, preferably, the spray-drying has an inlet air temperature of 150-180 ℃ and an outlet air temperature of 90-106 ℃; further preferably, the air inlet temperature of the spray drying is 165 ℃ and the air outlet temperature is 98 ℃;
preferably, the water content of the fenugreek extract powder is <6%.
10. Use of the fenugreek extract according to claim 5, the fenugreek tincture according to claim 7 or/and the fenugreek extract powder according to claim 9 in tobacco, electronic aerosolization additives, wines, drinks or cosmetics, characterized in that the fenugreek extract, the fenugreek tincture or/and the fenugreek extract powder have anti-inflammatory and anti-oxidative effects.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310288547.5A CN116515682A (en) | 2023-03-23 | 2023-03-23 | Strain, method for extracting fenugreek, preparation method and application of fenugreek extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310288547.5A CN116515682A (en) | 2023-03-23 | 2023-03-23 | Strain, method for extracting fenugreek, preparation method and application of fenugreek extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116515682A true CN116515682A (en) | 2023-08-01 |
Family
ID=87392956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310288547.5A Pending CN116515682A (en) | 2023-03-23 | 2023-03-23 | Strain, method for extracting fenugreek, preparation method and application of fenugreek extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116515682A (en) |
-
2023
- 2023-03-23 CN CN202310288547.5A patent/CN116515682A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105054040B (en) | A kind of composition of probiotics fermention ginseng and its preparation method and application | |
| CN108823261B (en) | Ultralow-molecular-weight dendrobium officinale polysaccharide and preparation and application thereof | |
| CN105174493B (en) | A kind of preparation method and applications of fermented type Chinese herbal medicine improver of water quality used for aquiculture | |
| WO2010098217A1 (en) | Immunopotentiating fermented food obtained from fructan-containing food | |
| CN112999127B (en) | Gentiana scabra bunge compound enzyme and preparation method and application thereof | |
| CN106755188A (en) | The preparation method and brown alga oligose of a kind of brown alga oligose monomer | |
| CN108186784B (en) | Dandelion composite enzyme and preparation method and application thereof | |
| CN113913346B (en) | Lactobacillus paracasei JN-1 and application thereof | |
| CN101822373B (en) | Golden-fungus gingko functional food, preparation method and use thereof | |
| CN110946196A (en) | Lithocarpus litseifolius electuary and preparation method thereof | |
| CN104497158A (en) | Method for extracting jujube polysaccharide | |
| CN105559068A (en) | Composition obtained by fermenting tetrastigma hemsleyanum diels et gilg. through edible and medicinal fungi and preparation method of composition | |
| CN117137131A (en) | Polygonatum sibiricum and wolfberry enzyme powder and preparation method thereof | |
| CN115212154B (en) | Preparation method of vine tea fermentation filtrate and application of vine tea fermentation filtrate in cosmetics | |
| CN109652479B (en) | Method for improving antioxidant capacity of dendrobe polysaccharide | |
| CN114982951B (en) | Preparation method of natural ginkgo enzyme | |
| CN116515682A (en) | Strain, method for extracting fenugreek, preparation method and application of fenugreek extract | |
| CN116407572A (en) | Sea buckthorn extract and preparation method and application thereof | |
| CN114231576B (en) | Application of lactobacillus reuteri in preparation of plant polysaccharide | |
| CN115414290A (en) | Traditional Chinese medicine composition with moisturizing, antioxidant and anti-inflammatory effects and preparation and application thereof | |
| CN106260359A (en) | A kind of Saussurea involucrata culture compositions Ganoderma tea and preparation method thereof | |
| CN106520377A (en) | Preparation method of fermented tobacco leaf extract capable of reducing irritation and application of fermented tobacco leaf extract to recombinant tobacco leaves | |
| Jia et al. | Cellulase of endophytic bacillus sp. from glycyrrhiza uralensis f. and its application for extraction of glycyrrhizic acid | |
| CN111387490A (en) | Preparation method of reinforced coupling blackberry enzyme | |
| CN112315867A (en) | Schisandra fruit rhodotorula mucilaginosa fermentation extract and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |